These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 10582905)
1. Comparative bacteriostatic and bactericidal activities of cefodizime against Borrelia burgdorferi sensu lato. Murgia R; Marchetti F; Cinco M Antimicrob Agents Chemother; 1999 Dec; 43(12):3030-2. PubMed ID: 10582905 [TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. Baradaran-Dilmaghani R; Stanek G Infection; 1996; 24(1):60-3. PubMed ID: 8852472 [TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone. Agger WA; Callister SM; Jobe DA Antimicrob Agents Chemother; 1992 Aug; 36(8):1788-90. PubMed ID: 1416868 [TBL] [Abstract][Full Text] [Related]
4. Comparative activity of cefodizime and ceftriaxone against respiratory pathogens in an in vitro pharmacodynamic model simulating concentration-time curves. Blandino G; Milazzo I; Musumeci R; Nicolosi VM; Speciale A; Nicoletti G J Chemother; 2000 Dec; 12(6):503-8. PubMed ID: 11154034 [TBL] [Abstract][Full Text] [Related]
5. Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis. Preac Mursic V; Marget W; Busch U; Pleterski Rigler D; Hagl S Infection; 1996; 24(1):9-16. PubMed ID: 8852456 [TBL] [Abstract][Full Text] [Related]
6. Sensitivity of Borrelia burgdorferi strains isolated in the Czech Republic. Janovská D; Hulínská D; Godová T Cent Eur J Public Health; 2001 Feb; 9(1):38-40. PubMed ID: 11243589 [TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto. Sicklinger M; Wienecke R; Neubert U J Clin Microbiol; 2003 Apr; 41(4):1791-3. PubMed ID: 12682190 [TBL] [Abstract][Full Text] [Related]
9. Lyme disease: disparity between culture and polymerase chain reaction detection of Borrelia burgdorferi after exposure to ceftriaxone in vitro. Varde S; Wormser GP; Nowakowski J; Nadelman RB; Bittker S; Cooper D; Schwartz I Conn Med; 1999 Oct; 63(10):589-91. PubMed ID: 10578549 [TBL] [Abstract][Full Text] [Related]
10. Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates. Hunfeld KP; Kraiczy P; Wichelhaus TA; Schäfer V; Brade V Int J Antimicrob Agents; 2000 Jun; 15(1):11-7. PubMed ID: 10856671 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease. Pavia CS; Wormser GP; Nowakowski J; Cacciapuoti A Antimicrob Agents Chemother; 2001 Mar; 45(3):936-7. PubMed ID: 11181384 [TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of cefodizime and other antibiotics against pathogens recently isolated in Italy. Nicoletti G; Blandino G; Cocuzza G; Dainelli B; Maida A; Debbia E; Schito G Chemotherapy; 1996; 42(2):100-6. PubMed ID: 8697884 [TBL] [Abstract][Full Text] [Related]
13. In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites. Kazragis RJ; Dever LL; Jorgensen JH; Barbour AG Antimicrob Agents Chemother; 1996 Nov; 40(11):2632-6. PubMed ID: 8913478 [TBL] [Abstract][Full Text] [Related]
14. Cefodizime: effects of sub-inhibitory concentrations on adhesiveness and bacterial morphology of Staphylococcus aureus and Escherichia coli: comparison with cefotaxime and ceftriaxone. Braga PC; Dal Sasso M; Maci S J Antimicrob Chemother; 1997 Jan; 39(1):79-84. PubMed ID: 9044031 [TBL] [Abstract][Full Text] [Related]
15. Antibiotics and increased temperature against Borrelia burgdorferi in vitro. Reisinger E; Wendelin I; Gasser R; Halwachs G; Wilders-Truschnig M; Krejs G Scand J Infect Dis; 1996; 28(2):155-7. PubMed ID: 8792482 [TBL] [Abstract][Full Text] [Related]
16. In vitro activities of faropenem, ertapenem, imipenem and meropenem against Borrelia burgdorferi s.l. Rödel R; Freyer A; Bittner T; Schäfer V; Hunfeld KP Int J Antimicrob Agents; 2007 Jul; 30(1):83-6. PubMed ID: 17512703 [TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of Borrelia burgdorferi isolates to three antibiotics commonly used for treating equine Lyme disease. Caol S; Divers T; Crisman M; Chang YF BMC Vet Res; 2017 Sep; 13(1):293. PubMed ID: 28962614 [TBL] [Abstract][Full Text] [Related]
18. New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances. Hunfeld KP; Kraiczy P; Wichelhaus TA; Schäfer V; Brade V Eur J Clin Microbiol Infect Dis; 2000 Jan; 19(1):27-32. PubMed ID: 10706176 [TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of cefodizime, cefuroxime, ceftriaxone against respiratory pathogens. Paniara O; Platsouka E; Dimopoulou H; Constantoulaki S J Chemother; 1994 Feb; 6(1):35-8. PubMed ID: 8071676 [TBL] [Abstract][Full Text] [Related]
20. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies. Dever LL; Jorgensen JH; Barbour AG J Clin Microbiol; 1992 Oct; 30(10):2692-7. PubMed ID: 1400969 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]